166 related articles for article (PubMed ID: 31827798)
1. Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma.
Andersson G; Lundgren S; Heby M; Nodin B; Elebro J; Jirström K
Biomark Res; 2019; 7():26. PubMed ID: 31827798
[TBL] [Abstract][Full Text] [Related]
2. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma.
Heby M; Lundgren S; Nodin B; Elebro J; Eberhard J; Jirström K
J Transl Med; 2018 Mar; 16(1):66. PubMed ID: 29540182
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
4. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
5. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.
Elebro J; Heby M; Gaber A; Nodin B; Jonsson L; Fristedt R; Uhlén M; Jirström K; Eberhard J
J Transl Med; 2014 Oct; 12():289. PubMed ID: 25323550
[TBL] [Abstract][Full Text] [Related]
8. Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer.
Luoh SW; Ramsey B; Park B; Keenan E
Breast J; 2014; 20(1):46-52. PubMed ID: 24261828
[TBL] [Abstract][Full Text] [Related]
9. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
10. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.
Elebro J; Heby M; Warfvinge CF; Nodin B; Eberhard J; Jirström K
PLoS One; 2016; 11(4):e0153533. PubMed ID: 27070783
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
12. Steroid hormone receptors and long term survival in invasive ovarian cancer.
Münstedt K; Steen J; Knauf AG; Buch T; von Georgi R; Franke FE
Cancer; 2000 Oct; 89(8):1783-91. PubMed ID: 11042574
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
14. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.
Seeliger H; Pozios I; Assmann G; Zhao Y; Müller MH; Knösel T; Kreis ME; Bruns CJ
BMC Cancer; 2018 Oct; 18(1):1049. PubMed ID: 30373552
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
Yang XY; Xi MR; Yang KX; Yu H
Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.
Heby M; Elebro J; Nodin B; Jirström K; Eberhard J
BMC Clin Pathol; 2015; 15():10. PubMed ID: 26028992
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
19. Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor.
Hwang KT; Suh YJ; Park CH; Lee YJ; Kim JY; Jung JH; Kim S; Min J;
Oncologist; 2021 Nov; 26(11):e1939-e1950. PubMed ID: 34402131
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]